Fundraising Fox
/Companies
Sign in

Pulmotect

Houston, US · 2 known investors

Find your way into Pulmotect

Sign up to see every warm intro you have to Pulmotect

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Pulmotect team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Pulmotect develops immunomodulatory inhaled therapies designed to activate the lungs' innate immune system for preventing and treating respiratory complications in immunosuppressed patients and other high-risk populations. The company is advancing PUL-042, a patent-protected therapy being evaluated in clinical trials.

BiotechHealthtechMedical Devices

Founders & leadership

CB
Colin BroomExecutive

Board

KS
Kumar SrinivasanBoard director
AV
Atul VaradhacharyBoard director
LE
Leo E. LinbeckBoard director
BS
Brenton ScottPresident and Chief Operating Officer, Co-founder
MWMark Worscheh
Mark WorschehBoard directorGeneral Partner at Fannin Goldenrod Holdings
LL
Leo Linbeck IIIBoard directorGeneral Partner at Fannin Goldenrod Holdings
MH
Magnus HookBoard director
BG
Bruce GivenBoard director

Investors · 2

Fannin Goldenrod HoldingsinferredHouston

How we know: board seat on SEC Form D · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$26.8M disclosed across 6 rounds · 2016–2024

▶$10.3MraisedSep 2024 · 15 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Kumar SrinivasanDirector
  • Magnus HookDirector
  • Atul VaradhacharyDirector
  • Colin BroomExecutive Officer, Director
  • Bruce GivenDirector
  • Leo E. LinbeckDirector
  • Brenton ScottDirector
Amount sold
$10.3M
Proceeds to insiders
$726.8K
First sale
Aug 2024
Incorporated
Corporation, Texas
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3.7MraisedJan 2024 · 11 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Kumar SrinivasanDirector
  • Brenton ScottExecutive Officer
  • Atul VaradhacharyDirector
  • Magnus HookDirector
  • Colin BroomExecutive Officer, Director
  • Bruce GivenDirector
  • Leo E. Linbeck IIIDirector
Amount sold
$3.7M
Finders' fees
$7.5K
Proceeds to insiders
$1.2M
Placement agents
16 Points LLC
First sale
Jan 2022
Incorporated
Corporation, Texas
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.5MraisedSep 2023 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Bruce GivenDirector
  • William NossExecutive Officer
  • James GamettDirector
  • Colin BroomExecutive Officer, Director
  • Atul VaradhacharyDirector
  • Brenton ScottExecutive Officer
  • Kumar SrinivasanDirector
  • Leo E. Linbeck IIIDirector
  • Magnus HookDirector
Amount sold
$1.5M
First sale
May 2023
Incorporated
Corporation, Texas
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3.5MraisedMar 2021 · 21 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Brenton ScottExecutive Officer
  • Colin BroomExecutive Officer, Director
  • Kumar SrinivasanDirector
  • Mark BenedykDirector
  • Atul VaradhacharyDirector
  • Bruce GivenDirector
  • Leo Linbeck IIIDirector
  • Magnus HookDirector
Offering amount
$3.5M
Amount sold
$3.5M
Sales commissions
$17.6K
Placement agents
16 Points LLC
First sale
Mar 2021
Incorporated
Corporation, Texas
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$6.1MraisedFeb 2020 · 22 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Brenton ScottExecutive Officer
  • Colin BroomExecutive Officer, Director
  • Kumar SrinivasanDirector
  • Bruce GivenDirector
  • Mark BenedykDirector
  • Leo Linbeck IIIDirector
  • Magnus HookDirector
  • Atul VaradhacharyDirector
Amount sold
$6.1M
First sale
Feb 2018
Incorporated
Corporation, Texas
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.8MraisedMay 2016 · 5 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Brenton ScottExecutive Officer, Promoter
  • Mark WorschehDirector
  • Bruce GivenDirector
  • Magnus HookDirector
  • Atul VaradhacharyDirector
  • Leo Linbeck IIIDirector
Offering amount
$2.5M
Amount sold
$1.8M
First sale
Apr 2016
Incorporated
Corporation, Texas
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 1

PulmocidePulmocide is a biopharmaceutical company developing inhaled therapies for difficult-to-treat respiratory diseases, currently focused on respiratory fungal infections such as pulmonary aspergillosis. Its lead investigational drug, opelconazole, is an inhaled antifungal agent in Phase 3 trials for patients with invasive pulmonary aspergillosis not responding to standard care.

Companies working in the same space as Pulmotect.

Frequently asked questions

What does Pulmotect do?
Pulmotect develops immunomodulatory inhaled therapies designed to activate the lungs' innate immune system for preventing and treating respiratory complications in immunosuppressed patients and other high-risk populations. The company is advancing PUL-042, a patent-protected therapy being evaluated in clinical trials.
Who are Pulmotect's investors?
Pulmotect's investors include Texas Ventures, Fannin Goldenrod Holdings.
How much funding has Pulmotect raised?
Pulmotect has disclosed $26.8M raised across 6 rounds.
Where is Pulmotect headquartered?
Pulmotect is headquartered in Houston, US.